Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2005-06-30
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Our primary hypothesis is that smoking abstinence will result in impaired sustained attention accompanied by decreases in blood-oxygenation-level-dependent (BOLD) fMRI signal in regions associated with sustained attention including right fronto-parietal cortex, thalamus and reticular activation system. Abstinence may also result in performance-related increases in activation in brain regions associated with effortful processing including the anterior cingulate cortex. We also hypothesize that smokers during the satiated state will exhibit brain activity more similar to that of non-smokers.
In addition to task related brain responses, we will also measure changes in absolute regional cerebral blood flow (rCBF) and hypothesize that abstinence will result in significant decreases in regions associated with arousal (e.g., reticular activation system); information processing (e.g., thalamus); and emotional regulation (e.g., anterior cingulate cortex, prefrontal cortex).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neuroimaging Decision Making and Response Inhibition During Smoking Abstinence
NCT00672256
The Effects of Smoking Withdrawal On Resting State Functional Connectivity
NCT01632384
fMRI of Stress in Smoking Behavior
NCT01719471
Self-activation in Individuals With and Without Nicotine Dependence
NCT03170258
Linking Brain Network Dynamics to Imminent Smoking Lapse Risk and Behavior
NCT05572671
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Included smoker participants will smoke at least 10 cigarettes per day of a brand delivering at least 0.5 mg nicotine (by FTC method) for at least two years and have afternoon end tidal carbon monoxide (CO) concentrations of at least 10 ppm (confirming they are inhalers). Inclusion criteria for non-smoker participants is that they should have smoked less than 50 cigarettes in their lifetime, have not smoked or used any nicotine products during the last 6 months, and have afternoon end tidal CO of less than or equal to 5 ppm. In order to reduce variability and ensure comparable stimulus exposure, participants will be required to be right-handed, and have at least 20-30 corrected vision.
During a screening session, all aspects of the study will be described to subjects and informed consent will be acquired. Breath and saliva samples will be collected in order to verify smoking status; and paper-and-pencil measures of smoking history, nicotine dependence, and mood will be collected. Each subject will also complete a Brain Imaging and Analysis Center (BIAC) approved fMRI subject screening form. For females of child bearing potential, a blood sample will be taken for pregnancy testing. For all participants, a urine sample will be taken for illicit drug testing. Finally, each subject will be escorted to the hospital where they will view and be placed in a mock fMRI scanner for a short time in order to increase familiarity with study procedures. Subjects who meet all selection criteria will be scheduled for the remainder of sessions.
Participants will learn and practice a sustained attention task. The planned sustained attention task, called the rapid visual information processing task (RVIP) requires participants to identify series of three odd or three even numbers among a series of numbers presented one at a time on a computer monitor. A control task in which participants press a button when they see a '0' will also be practiced. Total task time is 15 minutes (practice version) and each participant will be required to complete as many as 8 practice versions or until 50% accuracy is achieved on two consecutive attempts. Training may require 2-8 visits but will not exceed 2 hours and 40 minutes in total duration. One practice version of the task will be conducted in the mock fMRI scanner.
Following the training period, smoker participants will complete two fMRI scans and non-smokers will complete one fMRI scan in which they will complete 1) undergo a five minute resting state BOLD scan, 2) two 12.5 minute versions of the RVIP and 3) a 12.5-minute 'cue-viewing' task in which they view pictures of people smoking. For the 'satiated' sessions, smoker participants will be instructed to smoke as usual before and after the session. For the 'abstinent' session, smoker participants will be required to quit smoking for 24 hours prior to the scan and 24 hours following the scan. Quitting will be verified using CO and salivary cotinine and nicotine levels collected at the time of the scan and a short session 24 hours after the scan. All smoker participants will be given information about quitting smoking for 48 hours and we will answer questions about quitting smoking. The order of the sessions-satiated first vs. abstinent first-will be randomly assigned.
One week after their second scan, participants will attend a 30-minute office visit in which they will complete questionnaires and the RVIP task.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Smokers not interested in quitting smoking
Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
Smoking Abstinence
Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Smoking Abstinence
Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. a brand that delivers (by Federal Trade Commission rated yields) at least 0.5 mg nicotine
3. have an expired air carbon monoxide reading of at least 10 ppm.
4. be in general good health
5. Participants with controlled medical conditions (e.g., hypertension) will be considered if treatment is not thought to interfere with fMRI measures or potentially ameliorate smoking withdrawal symptoms
Exclusion Criteria
2. uncomfortable (e.g., chronic pain),
3. confound results (e.g., psychiatric condition)
4. suffering from claustrophobia; abnormally afraid of closed-in places will be excluded from participation,
5. Current alcohol or drug abuse,
6. smokeless tobacco use, or use of nicotine replacement therapy or other smoking cessation treatment will also be a basis for exclusion and evaluated via a urine test.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Duke University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francis J McClernon, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Duke UMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duke University Medical Center
Durham, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00007082
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.